PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-30.55%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
-49.51%
Cost reduction while VET shows 126.11% growth. Joel Greenblatt would examine competitive advantage.
1.96%
Positive growth while VET shows decline. John Neff would investigate competitive advantages.
46.82%
Margin expansion while VET shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.08%
Other expenses growth less than half of VET's 107.92%. David Dodd would verify if advantage is sustainable.
20.59%
Operating expenses growth while VET reduces costs. John Neff would investigate differences.
-36.59%
Total costs reduction while VET shows 4.99% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-13.31%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
34.31%
EBITDA margin growth while VET declines. John Neff would investigate advantages.
-9.82%
Both companies show declining income. Martin Whitman would check industry conditions.
29.85%
Operating margin growth while VET declines. John Neff would investigate advantages.
60.54%
Other expenses growth 50-75% of VET's 105.15%. Bruce Berkowitz would examine cost efficiency.
-7.70%
Both companies show declining income. Martin Whitman would check industry conditions.
32.90%
Pre-tax margin growth while VET declines. John Neff would investigate advantages.
4.03%
Tax expense growth while VET reduces burden. John Neff would investigate differences.
-10.68%
Net income decline while VET shows 44.56% growth. Joel Greenblatt would examine position.
28.61%
Net margin growth below 50% of VET's 83.20%. Michael Burry would check for structural issues.
-10.86%
EPS decline while VET shows 40.00% growth. Joel Greenblatt would examine position.
-10.86%
Diluted EPS decline while VET shows 55.56% growth. Joel Greenblatt would examine position.
0.03%
Share count change of 0.03% while VET is stable. Bruce Berkowitz would verify approach.
0.15%
Diluted share change of 0.15% while VET is stable. Bruce Berkowitz would verify approach.